Literature DB >> 30483666

Glycated haemoglobin (HbA1c) for postmortem diagnosis of diabetes.

Delia Lepik1, Mailis Tõnisson2,3, Anne Kuudeberg1, Marika Väli1,4.   

Abstract

The study was conducted at the Estonian Forensic Science Institute in 2008-2014 as continuous part of our previous study of alcohol and premature death in Estonian men. Autopsy data from 504 cases of male deaths (ages 19-79) were collected and blood and urine samples for glycated haemoglobin (HbA1c), liver enzymes and alcohol concentration were analysed. The aim of our research was to find undiagnosed diabetes and diabetes risk cases postmortem on the basis of increased values of HbA1c. HbA1c was within the reference value 4.8%-5.9% (29-42 mmol/mol), in 88.1% (n = 444) of cases, below reference value in 2.4% (n = 12), in the risk group of diabetes, HbA1c 6.0%-6.4% (42-46 mmol/mol) was within 5.8% (n = 29), and HbA1c result of ≥6.5% (48 mmol/mol) manifested in 3.8% (n = 19) of cases. The higher the age, the more cases with HbA1c value ≥6.0% (42 mmol/mol) occurred. In the group of external causes of death (n = 348), the HbA1c value of ≥6.5% (48 mmol/mol) HbA1c occurred in four cases. The HbA1c value was ≥6.5% (48 mmol/mol) in 78.9% of 156 cases when the cause of death was disease, of which 58% were cardiovascular diseases. The prevalence of diabetes and diabetes risk was found lower compared to population-based study, as majority of the deceased were young and middle-aged males and no females were included. In the case of poisoning with narcotic substances, HbA1c was within the reference range. A negative correlation occurred between alcohol intoxication and HbA1c value. A positive correlation between ALT and HbA1c was found - the higher stage of liver damage correlated with the higher HbA1c level.

Entities:  

Keywords:  Forensic science; diabetes; forensic pathology; glycated haemoglobin; postmortem

Year:  2018        PMID: 30483666      PMCID: PMC6197130          DOI: 10.1080/20961790.2018.1452354

Source DB:  PubMed          Journal:  Forensic Sci Res        ISSN: 2471-1411


Introduction

Postmortem diagnosis of glucose metabolism disorders include acute complications of diabetes mellitus as causes of death can be difficult and vague because of the lack of characteristic morphological findings. Diabetes mellitus is one of the most common chronic diseases in many countries, and its occurrence continues to increase. According to International Diabetes Federation data there were 425 million people aged of 20–79 years with diabetes in the world in 2017, and one of two adults with diabetes are undiagnosed (212 million). In Europe, the number of people with diabetes was estimated to be 58 million in 2017 [1]. Studies on alcohol consumption, pre-diabetes and type 2 diabetes risks have different and inconsistent results, showing either a protective or harmful effect or a more complex relationship. Data from epidemiological studies indicate a protective effect of moderate alcohol consumption. No beneficial effect can be attributed to high alcohol consumption [2,3]. Many studies showed that heavy alcohol consumption is a major cause of chronic pancreatitis and a risk factor for type 2 diabetes mellitus and pancreatic cancer [4]. Influence may also depend on specific alcoholic beverages. High consumption of spirits and beer seemed to increase the risk of pre-diabetes and type 2 diabetes but high wine intake showed a reduced risk of pre-diabetes [5]. The persons having impaired fasting glucose (fasting serum glucose 6.1–6.9 mmol/L and 2 h glucose <7.8 mmol/L) or impaired glucose tolerance (fasting serum glucose <6.1 mmol/L and 2 h glucose 7.8–11.0 mmol/L) were referred to as pre-diabetes cases [5]. For diagnosing diabetes blood glucose should be determined, but as the blood glucose content decreases postmortem because of continuing metabolism, it is not practical to determine blood glucose. Glucose metabolism may be evaluated on the basis of the results of glycated haemoglobin which are not strongly affected by glucose metabolism postmortem [6-8]. The test plays a critical role in the management of a patient with diabetes, since it correlates well with both microvascular and, to a lesser extent, macrovascular complications and is widely used as the standard biomarker for the adequacy of glycaemic management [9]. The amount of HbA1c in the blood is dependent on mean glucose levels present during the 8–12 weeks preceding measurement, as HbA1c accumulates in red blood cells during their 120-day lifespan, and therefore it is useful for long-term blood glucose control in diabetics [10-12]. For revealing undiagnosed or poorly managed diabetes in a post-mortem context, HbA1c levels are useful for distinguishing diabetic ketoacidosis from starvation or alcoholic ketoacidosis, reveal death caused by hyperosmolar hyperglycaemic state [6,7,13-16] and diagnose fatal diabetic coma [17]. HbA1c is relatively stable for analysing postmortem samples [18-20] and correlates well with clinical samples [19]. Ensuring the diagnosis of diabetes mellitus by morphological findings is very difficult and in many cases it remains undiagnosed. Therefore, it is important to determine if HbA1c values are affected by other concomitant diseases in addition to diabetes and if it is associated with cause of death due to external causes (injury). The first aim of our research was to find undiagnosed diabetes cases and diabetes risk cases postmortem on the basis of increased values of glycated haemoglobin. The second aim was to find changes in the values of liver enzymes, alanine aminotransferase (ALT), aspartate aminotransferase (AST) and gamma glutamyl transferase (GGT), and the association between liver enzymes and glycated haemoglobin in chronic alcohol abusers in addition to liver damage diagnosed on the basis of macroscopic findings and to find out cases of possible secondary diabetes.

Materials and methods

The study was conducted at the Estonian Forensic Science Institute in 2008–2014 as continuous part of our previous study of alcohol and premature death in Estonian men. The study target population was all deaths in Estonia subject to forensic autopsy of men aged over 18 years. The criterion for inclusion into the present study was possibility to obtain vitreous humour and blood. At autopsy, blood was collected from peripheral vessels, usually from femoral vein, with 20 mL syringe and 14-gauge needle. Blood was collected into 10 mL vacutainer tubes – in an EDTA tube for glycated haemoglobin and one plain vacutainer for liver enzymes and with sodium fluoride for blood alcohol concentration. Urine was taken directly from the bladder with 20 mL syringe and 14-gauge needle. There was also one plain tube for urine. Urine samples were collected for alcohol and narcotics. Vitreous humour was aspirated from both eyes using a syringe. The samples were refrigerated at 4 °C in the Forensic Science Departments of the Estonian Forensic Science Institute (EFSI) and dispatched at the same temperature conditions to the Southern Estonian Department within 24 h. For the determination of liver enzymes, blood was centrifuged at 2 100 r/min for 15 min in Eppendorf cooled centrifuge 4 °C and thereafter the serum was removed. If it was not possible to get serum, this case was excluded from the study. Data from the remaining 504 cases was used in the analysis. EDTA-blood for the determination of HbA1c and serum for the determination of liver enzymes were sent to the United Laboratories of the Tartu University Hospital. Vitreous humour was used for other studies. ALT and AST levels were measured using the kinetic photometric method as following: ALT and AST according to International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) with pyridoxal phosphate activation (Cobas 6000, Roche) – in vitro tests for the quantitative determination of ALT and AST with pyridoxal phosphate activation in human serum and plasma on Roche/Hitachi cobas c systems. Both tests’ measuring range is 5–700 U/L (0.08–11.7 μkat/L) and lower detection limit 5 U/L (0.08 μkat/L), and precision was determined using human samples and controls in an internal protocol with repeatability (n = 21) and intermediate precision (3 aliquots per run, 1 run per day, 20 days). The consensus measuring ranges (IFCC) for ALT and AST are <50 U/L in men and <35 U/L in women. GGT levels were measured with the kinetic colorimetric method as in the following: γ-Glutamyltransferase ver.2 Standardized against IFCC/Szasz (Cobas 6000, Roche) – in vitro test for the quantitative determination of γ-glutamyltransferase (GGT) in human serum and plasma on Roche/Hitachi cobas c systems. Measuring range is 3–1 200 U/L (0.05–20.0 μkat/L) and lower detection limit of the test 3 U/L (0.05 μkat/L), and precision was determined using human samples and controls in an internal protocol with repeatability (n = 21) and intermediate precision (3 aliquots per run, 1 run per day, 21 days). The consensus measuring ranges (IFCC) for GGT are <60 U/L in men and <40 U/L in women. HbA1c was measured using the Tina-quant Hemoglobin A1c Gen.3 – Hemolysate Application – Standardized according to IFCC transferable to Diabetes Control and Complications Trial/National Glycohemoglobin Standardization Program (DCCT/NGSP) (Cobas Integra 400 plus, Roche) – in vitro test for the quantitative determination of mmol/mol of hemoglobin A1c (IFCC) and percentage of hemoglobin A1c (DCCT/NGSP) in hemolysate prepared from whole blood on Roche clinical chemistry analysers. The HbA1c determination is based on the turbidimetric inhibition immunoassay (TINIA) for hemolyzed whole blood. The final result is expressed as mmol/mol or percentage of HbA1c and is calculated from the HbA1c/Hb ratio. Measuring range of 23–196 mmol/mol HbA1c (IFCC) and 4.2%–20.1% HbA1c (DCCT/NGSP) at a typical haemoglobin concentration of 8.2 mmol/L (13.2 g/dL). Lower limits of measurement: accordingly limit of blank and limit of detection for Hb 0.31 mmol/L and 0.62 mmol/L and for HbA1c 0.12 mmol/L and 0.18 mmol/L. Repeatability and intermediate precision were determined using human samples and controls in accordance with the Clinical and Laboratory Standards Institute (CLSI) EP5 requirements (2 aliquots per run, 2 runs per day, 21 days). For the assessment of laboratory results, Tartu University Hospital’s United Laboratories reference values for patients/living persons were used. The reference values for live persons are as follows: ALT <41 U/L, AST <38 U/L and GGT <61 U/L [20]. The reference values for HbA1c are as follows: normal value 4.8%–5.9% (by the IFCC 29–42 mmol/mol), below reference value <4.8% (<29 mmol/mol), risk group for diabetes 6.0%–6.4% (42–46 mmol/mol), diabetes mellitus ≥6.5% (≥48 mmol/mol) [21]. Urine and blood alcohol concentrations (BAC) were measured at the Chemistry Laboratory of the EFSI using headspace gas chromatography. Urine samples were screened in EFSI for narcotics, using a rapid urine test (Multiscreen 10 MTD; Biomedical Diagnostics) for measure of amphetamine, methamphetamine, cocaine, ecstasy, morphine, methadone, cannabis metabolite Δ-tetrahydrocannabinole, benzodiazepines, barbiturates and tricyclic antidepressants. Where screening results were positive, further confirmatory analysis was undertaken in EFSI using combined gas chromatography and mass spectrometry. For each case a study record was completed to which the record number, the EFSI Department, the autopsy number, and the deceased's date of birth, age, date of death and date of autopsy were entered using general data. Of more specific data, macroscopic, microscopic and laboratory findings (ethanol concentration, concentration of alcohol surrogates, illegal and legal drugs, liver enzymes and HbA1c) were documented retrospectively. Cause of death according to ICD code, manner of death, main disease and concomitant diseases were added to the record summary. The causes of death were classified on morphological and toxicological bases. The data were analysed by the following age groups: ≤29 years, 30–39 years, 40–49 years, 50–59 years and ≥60 years. Statistical analysis was performed using the Statistica 13.0 statistical program. Spearman rank order correlation (denoted as r), multiple response items and factorial dispersion analysis were used to assess bivariate relationships. The descriptive statistics were used to analyse cases’ general data. A P-value <0.05 was considered statistically significant.

Results

Autopsy data from 504 cases of male deaths (ages 19–79) were collected and samples were analysed. HbA1c was within the reference value 4.8%–5.9% (29–42 mmol/mol) in 88.1% (n = 444) of cases, HbA1c was below reference value in 2.4% (n = 12), in the risk group of diabetes, HbA1c 6.0%–6.4% (42–46 mmol/mol) was within 5.8% (n = 29), and HbA1c result of ≥6.5% (48 mmol/mol) manifested in 3.8% (n = 19) of cases. Previously was known to have diabetes in five males.

Age and HbA1c values

Eighty-five per cent of the deceased were aged 30–60 years. The largest age group was 40–49 years old, 38.1% of all investigated deaths. The higher the age, the more cases with HbA1c value of >6.0% (42 mmol/mol) occurred (r = 0.2, P < 0.05). In an age group ≤29 years there was only one case where the HbA1c value was ≥6.5% (48 mmol/mol) (a 26-year-old youth who died of gastrointestinal haemorrhage and who had alcoholic liver steatosis as the main disease. There was a previous history of diabetes). In the 30–39 age group there were six cases with a HbA1c value of > 6.0% (42 mmol/mol) and one case with a HbA1c value of ≥6.5% (48 mmol/mol); in the 40–49 age group there were 12 cases with a HbA1c value of > 6.0% (42 mmol/mol) and 4 cases with a HbA1c value of ≥6.5% (48 mmol/mol); in the 50–59 age group there were 11 HbA1c values of > 6.0% (42 mmol/mol) and 11 values of ≥6.5% (48 mmol/mol) (that is 45.8% of all values of > 6.0% (42 mmol/mol)); in the ≥60 age group there were two cases with a HbA1c value of ≥6.5% (48 mmol/mol). The age distribution of subjects and HbA1c values are presented in Table 1.
Table 1.

The age distribution of subjects and HbA1c values.

Age group (years)N<4.8%4.8%–5.9%6.0%–6.4%≥6.5%
29661 (1.5%)64 (96.7%)01 (1.5%)
30–391132 (1.8%)104 (92.0%)6 (5.3%)1 (0.9%)
40–491926 (3.1%)170 (88.5%)12 (6.3%)4 (2.1%)
50–591243 (2.4%)99 (79.8%)11 (8.9%)11 (8.9%)
≥60907 (77.8%)02 (22.2%)
Total50412 (2.4%)444 (88.1%)29 (5.8%)19 (3.8%)
The age distribution of subjects and HbA1c values.

Cause of death and HbA1c values

On the basis of the cause of death we established the following study groups: (1) external causes of death (n = 348): injury, other external causes (hypothermia, electrocution), drowning, hanging, other asphyxias (e.g. asphyxia with foreign bodies, inhalation of gastric contents), alcohol poisoning, illegal drug poisoning, fire fatality (e.g. carbon monoxide poisoning, burns of multiples body regions), (2) diseases (n = 156): cardiovascular diseases (chronic ischaemic heart disease, myocardial infarction, alcoholic and hypertrophic cardiomyopathy, hypertensive diseases), alcoholic liver disease and other diseases (pneumonia, haemorrhagic gastritis). Cause of death, age and levels of HbA1c, ALT, AST, GGT and BAC are presented in Table 2.
Table 2.

Cause of death, age and levels of HbA1c, ALT, AST, GGT and BAC.

  Age (years)
HbA1c (% (mmol/mol))
ALT (U/L)
AST (U/L)
GGT (U/L)
BAC (mg/g)
Cause of deathnRangeMedianRangeMedianRangeMedianRangeMedianRangeMedianRangeMedian
Injury8221–5439.54.8–6.4 (29–46)5.4 (36)35–28 90068999–19 850983.515–1 455580–4.32.0
Other external causes1932–5845.04.7–6.2 (28–44)5.5 (37)51–9 37427382–5 71781426–94759.50–3.20.0
Drowning2626–5441.04.8–5.9 (29–42)5.4 (36)32–4 792268172–2 03974721–348900–3.92.3
Hanging9119–6844.04.9–8.4 (30–68)5.5 (37)57–439 5001 342134–195 2001 11221–32776.50–4.01.4
Others asphyxias3420–6641.05.0–6.6 (31–47)5.5 (37)112–5 919639156–6 20889730–1 6081240–6.31.5
Fatal alcohol abuse4329–5446.04.8–6.9 (29–52)5.4 (36)40–17 00048363–9 98494529–7251240–6.63.9
Drug intoxication3625–4328.04.5–5.9 (26–42)5.3 (34)165–42 5801 833287–24 5401 66434–1 1021230–2.70.0
Fire fatality1726–5846.04.3–5.7 (24–39)5.3 (34)45–29 898745116–17 65361334–1 1021230–4.42.7
Cardiovascular diseases8731–7947.04.3–10.7 (24–93)5.6 (38)29–8 363906122–9 8171 02620–1 884890–3.80.0
Alcoholic liver disease3526–6048.04.5–6.9 (26–52)5.5 (37)101–13 7931 078237–13 0501 84747–9883400–2.60.0
Others diseases3429–5447.04.7–9.9 (28–85)5.6 (38)49–11 172771.5106–9 5961 266.523–900820–2.80.0

BAC: blood alcohol concentration.

Cause of death, age and levels of HbA1c, ALT, AST, GGT and BAC. BAC: blood alcohol concentration. In the group of external causes of death, an HbA1c value of ≥6.5% (48 mmol/mol) HbA1c occurred in four cases (1.1%): in two cases the cause of death was mechanical asphyxia (hanging), in one case other asphyxiation (aspiration of vomit) and in one case ethanol poisoning. In the case of acute alcohol poisoning the HbA1c value was 4.8%–6.9% (29–52 mmol/mol) (median 5.4% (36 mmol/mol)) and in the case of poisoning with narcotic substances, and in the injury and hanging groups, HbA1c was within the reference range (median 5.4% (36 mmol/mol)). A negative correlation occurred between alcohol intoxication and HbA1c value (r = −0.1, P < 0.05). In the whole study group 54.6% of the deceased ethanol was found in blood. In the diseases group, in 78.9% (n = 123) of cases the HbA1c value was ≥6.5% (48 mmol/mol), of which 57.9% were cardiovascular diseases. In the alcoholic liver damage group, the HbA1c of value ≥6.5% (48 mmol/mol) occurred in two cases. In previously known diabetes patients (n = 5) HbA1c values were as in the following: 9.9% (85 mmol/mol) in male whose cause of death was ischaemic heart disease, 10.7% (93 mmol/mol) in male with myocardial infarction, 5.6% (38 mmol/mol) in male with other unspecified heart disease, and 6.2% (44 mmol/mol) and 9.44% (78 mmol/mol) in two cases with pneumonia. On the basis of forensic autopsy findings diabetes was diagnosed only in one case where it was previously undiagnosed and where the direct cause of death was myocardial infarction; the biochemical characteristics were: HbA1c 8.93% (74 mmol/mol), ALT 2 415 U/L, AST 1 439 U/L and GGT 28 U/L.

Comorbidities and HbA1c values

Cardiovascular diseases occurred in 75% of all deceased, of which 47.2% (n = 238) were atherosclerosis of the aorta and coronary arteries, 4.8% (n = 24) hypertension, 3.2% (n = 16) alcoholic cardiomyopathy, 3.2% (n = 16) dilating cardiomyopathy, 4.5% (n = 23) hypertrophic cardiomyopathy, 11.7% (n = 59) chronic ischaemic heart disease and 0.4% (n = 2) other cardiovascular diseases (valve defect, myocarditis). Of the cases, 19.8% (n = 100) were without concurrent cardiovascular pathology and in 26 cases no data were reported about cardiovascular pathology. Of the deceased with HbA1c value ≥6.0% (42 mmol/mol), 33.4% (n = 15) had ischaemic heart disease as well as atherosclerosis of the aorta and coronary arteries, 11.1% (n = 5) had hypertrophic cardiomyopathy and other pathologies occurred as single cases. In two cases with an HbA1c value ≥6.0% (42 mmol/mol) no cardiovascular diseases occurred. Liver diseases occurred in 58% of subjects, of which focal steatosis made up 22.6% (n = 114), diffuse steatosis 25.8% (n = 130), incomplete fibrosis 2.4% (n = 12), incomplete cirrhosis 3.8% (n = 19) and alcoholic liver damage 3.6% (n = 18). Without liver pathology were 34.9% (n = 176) and in 35 cases had no microscopically data. With an HbA1c value ≥6.0 (42 mmol/mol) there was focal liver steatosis of 35.6%, diffuse steatosis of 28.9%, cirrhosis of 4.5% and alcoholic liver damage of 2.2%. Of these, 24.2% had no liver pathology (in other cases the microscopically pathology were not determined). Pancreatic diseases were found in 14.5% (n = 73), of which there were 5 cases of acute pancreatitis and 68 cases of chronic pancreatitis; in 65.9% (n = 332) cases no pathology occurred (in 99 cases it was not possible to determine pancreatic pathology). In subjects with HbA1c value ≥6.0% (42 mmol/mol) acute pancreatitis occurred in 2.2% (n = 3) and chronic pancreatitis in 15.6% (n = 7), no pancreatic pathology occurred in 64.4% of the cases (in other cases the microscopically pathology were not determined). In the case of mechanical asphyxiation, atherosclerosis of the aorta and coronary arteries was diagnosed as a concomitant disease, in one case hypertension and liver lipidosis; in the case of other asphyxiation the concomitant diseases were dilating cardiomyopathy and liver lipidosis; and in the case of alcohol poisoning ischaemic heart disease was diagnosed as the concomitant disease. The positive correlation between ALT and HbA1c (r = 0.139 3, P < 0.05) was found: the higher the stage of damage the higher the HbA1c level. High GGT values occurred in the liver alcoholic damage group. Liver alcoholic damage occurred in 35 cases with a GGT activity median of 340 U/L. The value of the GGT value was also significantly higher than in other cause of death groups (P < 0.05). The increase of GGT activity correlates with the risk of death due to atherosclerosis of the coronary arteries and other heart diseases. Table 3 shows the association of liver pathology with HbA1c value and ALT, AST and GGT.
Table 3.

The association of liver pathology with HbA1c value and ALT, AST and GGT mean value.

Liver pathologyHb1Ac (% (mmol/mol))ALT (U/L) MeanAST (U/L) MeanGGT (U/L) Mean
Without pathology4.8–5.9 (2942)2 802.12 075.979.6
 6.0–6.4 (42–46)6 333.44 510.486.0
 >6.4 (46)1 264.01 375.047.5
Focal steatosis4.8–5.9 (2942)8 321.04 663.4121.3
 6.0–6.4 (42–46)4 009.02 788.3100.3
 >6.4 (46)3 449.61 590.6126.0
Diffuse steatosis<4.8 (29)1 173.52 895.5475.0
 4.8–5.9 (2942)2 382.82 837.8277.5
 6.0–6.4 (42–46)1 797.81 554.9146.5
 >6.4 (46)1 997.33 643.0178.0
Fibrosis4.8–5.9 (29–42)1 350.11 513.3279.0
Cirrhosis<4.8 (29)203.0931.0787.5
 4.8–5.9 (2942)3 186.74 614.8280.7
 6.0–6.4 (42–46)4 687.02 384.0199.0
 >6.4 (46)72.0151.0410.0
Alcoholic liver damage<4.8 (29)420.01 562.0947.0
 4.8–5.9 (29–42)779.11 338.5284.3
 6.0–6.4 (42–46)247.0909.0352.0
The association of liver pathology with HbA1c value and ALT, AST and GGT mean value.

Discussion

The postmortem determination of complications of diabetes mellitus is difficult depending on the duration of disease. The changes as pancreas islet loss, atherosclerosis, microangiopathy, retinopathy, nephropathy and neuropathy are non-specific signs. Qualitative tests with stripes and tablets (glucose, bilirubin or acetone) or also by using electronic test devices may help to confirm or exclude certain suspected diagnoses [17]. In one study it was found that the calvariae of the diabetics showed reduced brightness and degree of the darker colour was correlated with the duration of illness [22]. The other researchers did not detect colour differences between diabetics and non-diabetics, but found correlation between yellowish bone colour and the subjects’ age [23]. The recent study has shown significant correlation of bone yellowing with HbA1c and age [24] and it is suggested that it is due to accumulation of advanced glycation end products produced in the Maillard or browning reaction by non-enzymatic means [25]. Histological examinations can reveal diabetic glomerulosclerosis (Kimmelstiel Wilson syndrome or nodular glomerulosclerosis) due to angiopathy of capillaries of renal cortex and glycogen nephrosis in cases long-lasting high hyperglycaemia (Armanni-Ebstein cells in straight sections of the proximal tubules) [26,27]. Biochemical analyses, including blood glycated haemoglobin, fructosamin [8,20,28] and anhydroglucitol [29,30], determination, may complement postmortem investigations and provide useful information for determining the cause of death even in corpses with advanced decomposition. In post-mortem specimens, HbA1c was found stable from 4 to 36 h [18] or for at least 72 h (72 or more hours following death) [19,20], and EDTA was found to be preferable preservative, as samples can be measured after four weeks storage at 4 °C [13]. But interpretation of biochemical analyses is difficult because of postmortem blood alterations involving glucose metabolic pathways. For comparison of the clinical and postmortem results, the measurement of blood glycated haemoglobin was chosen because fructosamin or anhydroglucitol is not used for glycaemic control in clinical laboratories in Estonia. In Estonia, the adults (20–79 years old) with diabetes were estimated to be 55 000 people, diabetes age-adjusted comparative prevalence 4.0%, adults with undiagnosed diabetes 19 800 and diabetes-related deaths 544 [1]. By International Expert Committee report on the use of the HbA1c assay in the diagnosis of diabetes, diabetes should be diagnosed when HbA1c is ≥6.5% (48 mmol/mol). Individuals with an HbA1c level ≥6% (42 mmol/mol) but ˂6.5% (48 mmol/mol) are at the highest risk for progression to diabetes [31]. In our study, most HbA1c values were within the limits of the reference value 4.8%–5.9% (29–42 mmol/mol)); 5.8% of cases had values indicating diabetes risk and 3.8% with diabetes mellitus. At the same time, we saw that the higher the age the more frequently the HbA1c value is ≥6.0% (42 mmol/mol). As majority of the deceased were young and middle-aged males and no females were included in our study group, therefore, prevalence of diabetes and diabetes risk was found lower compared to population-based study. Chen et al. [32] have found that hyperglycaemia was frequently detected in mechanical asphyxiation, saltwater drowning, cerebrovascular disease, ischemic heart disease and electrocution. In deaths caused by external causes we found high HbA1c values only in individual cases, all with concomitant cardiovascular diseases; therefore, it is reasonable to think that the increase of HbA1c is caused by the diseases, not external causes. Although the relationship between cardiovascular disease and glycaemia is believed to represent a continuum without a threshold effect, HbA1c might offer more advantages in terms of prognostic information, as it is a more stable, accurate parameter of glucose homeostasis. Persistent elevations in blood sugar (therefore HbA1c) increase the risk of long-term vascular complications of diabetes such as coronary disease, heart attack, stroke, heart failure, kidney failure, etc. [33,34]. HbA1c is a good marker of glycated proteins, which play a contributory role in atherosclerosis in both diabetic and non-diabetic individuals. We also achieved the similar result, as the HbA1c values were in range 4.3%–10.7% (24–93 mmol/mol), median 5.6% (38 mmol/mol) occurred in 87 cases with cardiovascular diseases, an HbA1c value ≥6.0% (42 mmol/mol) occurred with ischaemic disease, atherosclerosis of aorta and coronary arteries (33.4%) and when the HbA1c value was ≥6.5% (48 mmol/mol), 58% of cases included cardiovascular diseases. Our study also showed that the increase in HbA1c value 6.0%–6.4% (42–46 mmol/mol) occurs together with concomitant affecting cardiovascular diseases: atherosclerosis of the aorta and coronary arteries, hypertension and dilating cardiomyopathy. Among adults per capita alcohol consumption (in litres of pure alcohol) by type of alcoholic beverage was 41% beer, 37% spirits, 11% wine and 11% other in 2010 [35]. The “other alcohol” group contains surrogate non-beverage alcohols (ethanol-containing liquids not intended for consumption), which are drunk particularly among men in Estonia [36,37]. In a previous study of association of alcohol with the mortality of Estonian men aged 25–54 years, alcohol was found in blood in concentrations ≥ 0.2 mg/g in 55% cases of death [38]. Results of that study of men also showed evidence of alcohol-induced pathologies in 75% of cases, and 32% had pathologies in two or more organs [39]. Some types of alcohol-related purchases were associated with a lower prevalence of type 2 diabetes (T2D), and respondents who purchased the greatest volumes of wine or beer – but not liquor – were less likely to report being diagnosed with T2D in 2011–2012 than non-drinkers [40]. We found a negative correlation between alcohol intoxication and HbA1c value (r = −0.1, P < 0.05), as deceased in the acute alcohol intoxication group were relatively younger. The effects may be also caused by alcohol-induced hypoglycaemia [41]. In the whole study group 54.6% of the deceased ethanol was determined in blood. Lower-than-expected levels of HbA1c can be seen in people with shortened red blood cell lifespan, such as with glucose-6-phosphate dehydrogenase deficiency, sickle-cell disease or any other condition causing premature red blood cell death. A low HbA1c value occurred with carbon monoxide poisoning (2.4%) which may be associated with the ability of haemoglobin to bind carbon monoxide. In the case of poisoning by narcotic substances there are different opinions in the literature about HbA1c values, e.g. according to Chen et al. [32] the HbA1c value is lower in fatal methamphetamine abuse, probably from the starvation during the long-term abusing of methamphetamine. Palmiere et al. [15] showed that cocaine consumption provokes hyperglycaemia due to increases of adrenalin/noradrenalin level. Probably the HbA1c normal values found on the basis of this study may be explained by the fact that the fentanyl typically used in Estonia [42]. Fentanyl does not affect glucose metabolism or that mostly young people die as a result of poisoning with narcotic substances. The liver is an accumulator of glycogen and a regulator of glucose metabolism. Therefore when liver damage worsens, glucose metabolism is also impaired and the HbA1c level increases. With an HbA1c value ≥6.0% (42 mmol/mol), 35.6% had focal liver steatosis, 28.9% had diffuse steatosis, 4.5% cirrhosis and 2.2% alcoholic liver damage. Liver damage was absent in 24.2% of cases. With an HbA1c value ≥6.0% (42 mmol/mol) of pancreas damage acute pancreatitis occurred in 2.2% and chronic pancreatitis in 15.6% of cases. At the same time we know that autolysis makes the assessment of morphological findings of the pancreas difficult. Therefore, we see every day that it is not possible to assess pancreas findings. The increasing trends in alcoholic liver cirrhosis mortality in Estonia over the past two decades represent trends for chronic liver disease and cirrhosis in northern European countries [43]. Drastic reduction of the level of liver enzymes ALT and AST in the case of cirrhotic liver damage indicates liver failure in live subjects, but on the basis of these reference values it is not possible to find associations of ALT and AST with cause of death groups, as the same reference ranges cannot be used in deceased subjects. At the same time there was a positive correlation between ALT (and the enzyme associated more with liver damage than AST) and HbA1c in cause of death groups. An AST to ALT ratio over 2:1, characteristic to alcohol abuse, also occurred in our study in alcoholic liver disease groups. In the study by Ringmets et al. [38] it was stated that liver enzymes, used widely to detect liver damage in living subjects, have a limited postmortem value. AST and ALT are increased by haemolysis and hypoxia and so are subject to differences in the process of dying. GGT, as a marker of liver fibrosis and cirrhosis, is less affected by these processes. When determining the cause of death, only the GGT result of liver enzymes can be used to determine the cause of death (e.g. cirrhotic liver, chronical alcohol abuse). A strong dose-response relationship of serum GGT to cardiovascular mortality has been found [44]. The association with high GGT was consistent over all subgroups of disease with the exception of acute/subacute forms of coronary heart disease in men. However, this latter association was significant in men aged <60 years. Additionally, GGT was significantly associated with established risk factors such as triglycerides, body mass index and cholesterol. Adjustment for these variables in multiple risk factor regression analyses confirmed GGT as an independent predictive factor for cardiovascular mortality. However, the results in postmortem biochemistry in general do not have an absolute value, and they must be interpreted in the context of pathological findings and the circumstances of the death, and with information from multiple marker systems, to maximize their diagnostic value.

Conclusion

Since these diabetic complications are often involved in the causes of sudden death or contributors to other casualties, postmortem diagnosis of diabetes mellitus is important in routine forensic autopsy. HbA1c in blood is useful to investigate not only fatal metabolic disorders involved in diabetes mellitus but also death processes due to other causes.
  39 in total

1.  Gamma-glutamyltransferase as a risk factor for cardiovascular disease mortality: an epidemiological investigation in a cohort of 163,944 Austrian adults.

Authors:  Elfriede Ruttmann; Larry J Brant; Hans Concin; Günter Diem; Kilian Rapp; Hanno Ulmer
Journal:  Circulation       Date:  2005-09-26       Impact factor: 29.690

2.  Alcohol consumption and risk of pre-diabetes and type 2 diabetes development in a Swedish population.

Authors:  M Cullmann; A Hilding; C-G Östenson
Journal:  Diabet Med       Date:  2012-04       Impact factor: 4.359

Review 3.  Alcohol consumption and type 2 diabetes Meta-analysis of epidemiological studies indicates a U-shaped relationship.

Authors:  S Carlsson; N Hammar; V Grill
Journal:  Diabetologia       Date:  2005-04-30       Impact factor: 10.122

Review 4.  Moderate alcohol consumption lowers the risk of type 2 diabetes: a meta-analysis of prospective observational studies.

Authors:  Lando L J Koppes; Jacqueline M Dekker; Henk F J Hendriks; Lex M Bouter; Robert J Heine
Journal:  Diabetes Care       Date:  2005-03       Impact factor: 19.112

Review 5.  Alcohol and pancreatic cancer.

Authors:  Vay Liang W Go; Anna Gukovskaya; Stephen J Pandol
Journal:  Alcohol       Date:  2005-04       Impact factor: 2.405

6.  A rapid situation assessment of the market for surrogate and illegal alcohols in Tallinn, Estonia.

Authors:  Kersti Pärna; Katrin Lang; Kadi Raju; Marika Väli; Martin McKee
Journal:  Int J Public Health       Date:  2007       Impact factor: 3.380

7.  Measurement of Postmortem 1,5-anhydroglucitol in Vitreous Humor for Forensic Diagnosis.

Authors:  Tomoyo Takata; Yukie Yamasaki; Takashi Kitao; Satoru Miyaishi
Journal:  J Forensic Sci       Date:  2015-09-29       Impact factor: 1.832

8.  Clinical evaluation of measuring glycosylated hemoglobin levels for assessing the long-term blood glucose control in diabetics.

Authors:  M Inada; M Oishi; M Nishikawa; S Kurata; H Imura
Journal:  Endocrinol Jpn       Date:  1980-08

9.  Coronary artery disease in the developing world.

Authors:  Karen Okrainec; Devi K Banerjee; Mark J Eisenberg
Journal:  Am Heart J       Date:  2004-07       Impact factor: 4.749

10.  Investigation of markers to indicate and distinguish death due to alcoholic ketoacidosis, diabetic ketoacidosis and hyperosmolar hyperglycemic state using post-mortem samples.

Authors:  Joanna Hockenhull; Waljit Dhillo; Rebecca Andrews; Sue Paterson
Journal:  Forensic Sci Int       Date:  2011-08-12       Impact factor: 2.395

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.